This week, our Chief Scientific Advisor Bruce German and CEO Ishita M. Shah, Ph. D. attended the Women's Health Innovation Series Summit in Boston and took the opportunity to share some of our newest milestones during the Innovation Showcase. Many thanks to the organizers and the selection committee for this continued chance to reveal evolutionary secrets from milk towards clinical development of therapeutics for infectious diseases. We have a lot of exciting work ahead of us as we continue with our mission of improving women’s lives. #milk #antimicrobialpeptides #infectiousdiseases #womenshealth #WHIS2024
Matrubials Inc.
生物技术研究
Davis，California 232 位关注者
Developing milk-inspired therapies for infectious diseases
关于我们
Matrubials is developing milk-inspired therapies to reduce the burden of drug resistant infections. Our core mission is to address Bacterial Vaginosis which remains unresolved for women in reproductive ages, resulting in an umbrella of clinical complications including reproductive issues. We are simultaneously developing topical therapies for all-gender skin health using our AI-enabled platform for candidate expansion.
- 网站
-
https://matrubials.com/
Matrubials Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Davis，California
- 类型
- 私人持股
地点
-
主要
获取路线
US，California，Davis，95618
Matrubials Inc.员工
-
David A. Mills
Distinguished Professor, Peter J. Shields Chair in Dairy Food Science, UC Davis
-
Ishita M. Shah, Ph. D.
CEO and co-founder at Matrubials Inc (YC S21)
-
Chinmay Arora
Cell Biology at University of California, Davis
-
Amanda Batiste
Research Associate at Matrubials Inc. | Neurobiology, Physiology, and Behavior student at UCD
动态
-
I’m elated about attending the Boulder Peptide Symposium this week. It has been a fantastic conference with numerous insights into peptides from early discovery to clinical development. The talks and panel discussions were outstanding. I was of course delighted to share Matrubials Inc.s’ mission of impacting women’s health & ID using these power-packed molecules amidst such intellectuals and a view of the Flatirons. #peptides #therapeutics #infectiousdiseases #womenshealth #BPS2024
-
-
I’m truly looking forward to attending the Boulder Peptide Symposium next month, & sharing our mission during the Showcase session with esteemed colleagues. #peptides #antimicrobials #therapeutics #womenshealth #microbiome
JUST ANNOUNCED! Our day 1 Peptide Showcase session is FULL! We are so excited to hear from Alexander Pisarchik from Alcamena, Jeff Posakony, Ph.D. from AltPep, Jari Willems from Endoprotease Services, Karsten Eastman from Sethera Therapeutics, and Ishita M. Shah, Ph. D. from Matrubials Inc.. HURRY! Early-Bird registration ends Friday, July 26th! Register today at: https://lnkd.in/gtcdZW6a Thank you to our SAB members who helped make this session possible! Wendy Hartsock from Aralez Bio, Christopher McGee, Ph.D. from Bachem. #peptide #peptides #peptidechemistry
-
-
We’re so delighted to be a portfolio company!
This #FundedFriday, we are thrilled to announce the addition of Matrubials Inc. to the MinervaFund portfolio! Matrubials is using milk-inspired therapies for infectious diseases. Based out of UC Davis, this groundbreaking innovation provides safe solutions that can reduce the healthcare and economic burden resulting from bacterial infections and concomitant clinical complications. Learn more at https://lnkd.in/gUsnhDdF? #FundedbyMinervaVerse
-
-
Terrific time sharing our mission at #BIO2024’s Start-Up Stadium in San Diego! Thank you California Life Sciences (CLS) for this opportunity. Our work was well received, and we got excellent questions and feedback from the judges. #infectiousdiseases #antimimicrobialresistance #womenshealth #milk #antimicrobialpeptides #therapeutics
?? Exciting times at #BIO24 in San Diego! ?? California Life Sciences (CLS) is proud to support several female led, FAST alumni in the BIO International Convention Startup Stadium! Today we heard from Ishita M. Shah, Ph. D., CEO & Founder of Matrubials Inc., presenting their mission to "provide safe solutions that can reduce the healthcare and economic burden resulting from bacterial infections and concomitant clinical complications." Matrubials is developing novel antibacterial therapeutics to address non-selectivity and emerging antimicrobial resistance. View the presenters at this years Start-Up Stadium here: https://bit.ly/3Kui5TG Learn more about the California Life Sciences FAST program here: https://bit.ly/3KurQkF
-